The initiation of blood coagulation through the factor VII-Tissue Factor pathway is not only important for normal hemostasis, but likely plays a role in pathological thrombosis as well. Cellular expression of TF has been correlated with infectious, inflammatory, and neoplastic disease, and may be responsible in part for the thromboembolic complications of not only these illnesses, but also the venous thromboembolic and pulmonary embolism occurring in otherwise normal individuals as well. Plasma contains an endogenous inhibitor of the VII-TF complex which we call LACI. It is associated with the lipoproteins in plasma and requires the presence of Xa to express its feedback inhibition of VII-TF. We plan to further characterize LACI by isolating its cDNA, determining the spectrum and kinetics of its protease inhibition, and investigating the structure function relationships of the LACI molecule vis a vis its association with lipoproteins, its inhibition of Xa, and its relationship to the other components in the putative VII-TF-Xa-LACI inhibitory complex. Additional studies will also investigate the synthesis of TF and LACI by cells, determine the immunohistochemical localization of TF/LACI in normal and pathological tissues, and assess the relationship between TF and LACI blood concentrations and clinical disease. These studies will be performed using purified TF and LACI, fragments of them produced by proteolysis or chemical treatment (CnBr), their isolated cDNAs, synthetic peptides based on their predicted amino acid sequence, and appropriate monoclonal and polyclonal antibodies. The experiments are designed to provide information, now lacking, concerning the initiation and control of coagulation and the interrelationship between the classical """"""""extrinsic"""""""" and """"""""intrinsic"""""""" pathways. The results should enhance our understanding of both normal hemostasis and pathologic thromboembolism.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL034462-08
Application #
3347377
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1988-07-01
Project End
1993-06-30
Budget Start
1992-07-01
Budget End
1993-06-30
Support Year
8
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Barnes-Jewish Hospital
Department
Type
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63110
Ndonwi, M; Broze Jr, G (2008) Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. J Thromb Haemost 6:1044-6
Ndonwi, Matthew; Broze Jr, George J; Agah, Sayeh et al. (2007) Substitution of the Gla domain in factor X with that of protein C impairs its interaction with factor VIIa/tissue factor: lack of comparable effect by similar substitution in factor IX. J Biol Chem 282:15632-44
Ndonwi, M; Broze Jr, G; Bajaj, S P (2005) The first epidermal growth factor-like domains of factor Xa and factor IXa are important for the activation of the factor VII--tissue factor complex. J Thromb Haemost 3:112-8
Lu, Genmin; Broze Jr, George J; Krishnaswamy, Sriram (2004) Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III. J Biol Chem 279:17241-9
Forastiero, R R; Martinuzzo, M E; De Larranaga, G et al. (2003) Antibodies to tissue factor pathway inhibitor are uncommonly detected in patients with infection-related antiphospholipid antibodies. J Thromb Haemost 1:2250-1
Forastiero, R R; Martinuzzo, M E; Broze, G J (2003) High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome. J Thromb Haemost 1:718-24
Forastiero, R R; Martinuzzo, M E; Lu, L et al. (2003) Autoimmune antiphospholipid antibodies impair the inhibition of activated factor X by protein Z/protein Z-dependent protease inhibitor. J Thromb Haemost 1:1764-70
Eitzman, Daniel T; Westrick, Randal J; Bi, Xiaoming et al. (2002) Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden. Circulation 105:2139-42
Westrick, R J; Bodary, P F; Xu, Z et al. (2001) Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation 103:3044-6
Chan, J C; Carmeliet, P; Moons, L et al. (1999) Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit. J Clin Invest 103:475-82

Showing the most recent 10 out of 47 publications